G. Ferrari

发表

Combination treatment versus LHRH alone in advanced prostatic cancer.

P. Ferrari, G. Castagnetti, G. Ferrari, 1996, Urologia internationalis.

Combination treatment in M1 prostate cancer

P. Ferrari, G. Castagnetti, G. Ferrari, 1993, Cancer.

Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation.

S. Bettelli, M. Migaldi, G. Trentini, 1999, Journal of clinical pathology.

Does p53 immunostaining improve diagnostic accuracy in urine cytology?

G. Rossi, G. Trentini, C. De Gaetani, 1997, Diagnostic cytopathology.

Prognostic factors in renal cell carcinoma: Effect on prognosis of neoadjuvant and adjuvant treatments

P. Ferrari, G. Castagnetti, G. Ferrari, 1997 .

Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy.

A. Cesinaro, M. Migaldi, G. Trentini, 2000, Oncology research.

Lithiasis and Risk Factors

G. Galizia, P. Ferrari, G. Ferrari, 2007, Urologia Internationalis.

Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin.

P. Ferrari, G. Castagnetti, G. Ferrari, 1992, Anti-cancer drugs.

Echo-guided SWL of vesical stones with Dornier MPL 9000 lithotripter in obstructed and unobstructed patients.

S. Gaiani, M. Ronchi, P. Ferrari, 1998, Journal of endourology.

I markers biologici. Introduzione: Biological markers. Introduction

G. Castagnetti, G. Ferrari, B. Baisi, 1995 .

In situ echoguided extracorporeal shock wave lithotripsy of ureteric stones with the Dornier MPL 9000: a multicentric study group.

S. Gaiani, G. Corrado, M. Ronchi, 1994, British journal of urology.

Risk of fracture in celiac disease: gender, dietary compliance, or both?

E. Smecuol, H. Vázquez, E. Mauriño, 2011, World journal of gastroenterology.

Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon‐a2b versus interferon-α2b with epirubicin

P. Ferrari, G. Castagnetti, G. Ferrari, 1992 .